Industry Bulletins | June 24, 2022
VeriSIM Life & Total Brain Strategic Collaboration Focuses On AI To Develop New Drugs For Neurological Disorders
VeriSIM Life (VeriSIM), which provides an artificial intelligence (AI) solution to assess risk in pharmaceutical research and development, recently announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company. The strategic collaboration will focus on creating insights for the development of novel drugs to treat a wide range of neurological disorders including Alzheimer’s disease, Parkinson’s disease, schizophrenia, anorexia nervosa, depression, anxiety, and bipolar disorder among others.
The partnership will pioneer the integration of Total Brain’s proprietary mental health and brain performance database with VeriSIM Life’s BIOiSIM™ AI . . .